A drop of blood distinguishes Crohn's disease from ulcerative colitis...Laying the foundation for customized treatment of inflammatory bowel disease
Mar 27, 2025
Inflammatory bowel disease (IBD) is expected to be more accurate and personalized. Recently, Professor Lee Hong-seop's team at Inje University's Busan Paik Hospital announced a study that the difference between Crohn's disease and ulcerative colitis can be identified through molecular characteristics in the blood.
Existing methods of diagnosing inflammatory bowel disease had to rely on colonoscopy or biopsy, but the research team confirmed that multi-omics analysis through blood can more accurately determine disease types and conditions. Multi-omics is an approach that integrates and analyzes several biological data (omics) such as dielectrics, transcripts, proteins, and metabolites.
Professor Lee Hong-seop's research team analyzed proteins, metabolites, and lipids in serum from 18 patients with Crohn's disease and 57 patients with ulcerative colitis. As a result of the study, differences in chronic inflammation, phospholipid, and bile acid homeostasis were observed between the two disease groups. In patients with ulcerative colitis, combined bile acid levels were higher, and phospholipid composition was changed. Different biomarkers allow accurate distinguishing and precise diagnosis of Crohn's disease and ulcerative colitis.
In addition, the research team also discovered the difference between the two diseases through inflammation levels in feces (calprotectin).
High calprotectin levels showed an increase in inflammation-related proteins and sphingomyelin and were found to be associated with a decrease in bile acids, amino acids, and triglycerides. In particular, the biomarker's analysis also provided a basis for distinguishing whether inflammatory bowel disease is a 'active state' or a 'relief state' without symptoms. In the case of active diseases, inflammation-related proteins and triglycerides increased, but sphingomyelin showed reduced characteristics.
While most of the previous studies compared healthy controls with inflammatory bowel disease patients, this study is evaluated as reflecting the actual clinical environment well in that it targeted patients with inflammatory bowel disease who are already receiving treatment. In addition, it added significance in that it identified potential biomarker candidates that could be used for early diagnosis and customized treatment of inflammatory bowel disease.
Professor Lee Hong-seop "This study has contributed to the elucidation of complex molecular characteristics of inflammatory bowel disease. In the future, we plan to verify this result through larger longitudinal studies and clarify the causal relationship"We expect this to lay an important foundation for personalized management of inflammatory bowel disease and development of treatment strategies" The study was published in the recent issue of the SCIE-level journal 『Journal of Pharmaceutical and Biomedical Analysis』.
N2MT07||text parameter is needed (text 파라미터가 필요합니다.)
Existing methods of diagnosing inflammatory bowel disease had to rely on colonoscopy or biopsy, but the research team confirmed that multi-omics analysis through blood can more accurately determine disease types and conditions. Multi-omics is an approach that integrates and analyzes several biological data (omics) such as dielectrics, transcripts, proteins, and metabolites.
Professor Lee Hong-seop's research team analyzed proteins, metabolites, and lipids in serum from 18 patients with Crohn's disease and 57 patients with ulcerative colitis. As a result of the study, differences in chronic inflammation, phospholipid, and bile acid homeostasis were observed between the two disease groups. In patients with ulcerative colitis, combined bile acid levels were higher, and phospholipid composition was changed. Different biomarkers allow accurate distinguishing and precise diagnosis of Crohn's disease and ulcerative colitis.
In addition, the research team also discovered the difference between the two diseases through inflammation levels in feces (calprotectin).
High calprotectin levels showed an increase in inflammation-related proteins and sphingomyelin and were found to be associated with a decrease in bile acids, amino acids, and triglycerides. In particular, the biomarker's analysis also provided a basis for distinguishing whether inflammatory bowel disease is a 'active state' or a 'relief state' without symptoms. In the case of active diseases, inflammation-related proteins and triglycerides increased, but sphingomyelin showed reduced characteristics.
While most of the previous studies compared healthy controls with inflammatory bowel disease patients, this study is evaluated as reflecting the actual clinical environment well in that it targeted patients with inflammatory bowel disease who are already receiving treatment. In addition, it added significance in that it identified potential biomarker candidates that could be used for early diagnosis and customized treatment of inflammatory bowel disease.
Professor Lee Hong-seop "This study has contributed to the elucidation of complex molecular characteristics of inflammatory bowel disease. In the future, we plan to verify this result through larger longitudinal studies and clarify the causal relationship"We expect this to lay an important foundation for personalized management of inflammatory bowel disease and development of treatment strategies" The study was published in the recent issue of the SCIE-level journal 『Journal of Pharmaceutical and Biomedical Analysis』.
|
This article was translated by Naver AI translator.
